期刊
WORLD JOURNAL OF GASTROENTEROLOGY
卷 17, 期 4, 页码 419-432出版社
BAISHIDENG PUBLISHING GROUP INC
DOI: 10.3748/wjg.v17.i4.419
关键词
Pegylated interferon alpha; Ribavirin; Chronic hepatitis C virus infection; Difficult-to-treat patient; Individualized treatment; Response-guided therapy; Specifically targeted antiviral therapy for hepatitis C virus
Pegylated interferon alpha (IFN alpha) in combination with ribavirin is currently recommended as a standard-of-care treatment for chronic hepatitis C virus (HCV) infection. This combination therapy has drastically improved the rate of sustained virological response, specifically in difficult-to-treat patients. Recently, individualized treatment, such as response-guided therapy, is being developed based on host-, HCV- and treatment-related factors. Furthermore, modified regimens with currently available medications, novel modified IFN alpha and ribavirin or combinations with specifically targeted antiviral therapy for HCV agents, are currently being investigated. The purpose of this review is to address some issues and epoch-making topics in the treatment of chronic HCV infection, and to discuss more optimal and highly individualized therapeutic strategies for HCV-infected patients.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据